Sun, Mar 1, 2015, 8:44 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

patriot1045 21 posts  |  Last Activity: Feb 17, 2015 10:00 AM Member since: Nov 29, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • patriot1045 patriot1045 Feb 17, 2015 10:00 AM Flag

    Just a PR with good news and this will run as moving up on low volume!

    Sentiment: Strong Buy

  • Market Cap (Mil USD) 409 --- --- ---

    # of Institution Owners 89 --- --- ---

    # of Fund Owners 94 --- --- ---

    % Owned by Institutions 59.80 --- --- ---

    % Owned by Funds 14.42 --- --- ---

    % Owned by Insiders 4.68

    Sentiment: Strong Buy

  • Wednesday Trending Tickers: CareFusion Corporation (CFN), BlackRock Kelso Capital Corporation (BKCC), Northwest Biotherapeutics, Inc. (NWBO), Lifeway Foods Inc. (LWAY), Unum Group (UNM)

    Business

    by Kristina Gordon - Jan 21, 2015 3:46 am EST
    WallStreet Scope – January 21st 2015:

    Sentiment: Strong Buy

  • Northwest Biotherapeutics, Inc Price Target Update

    by Thomas Lindt on January 20, 2015

    Northwest Biotherapeutics, Inc (NASDAQ:NWBO): 1 Analyst have given the stock of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) a near short term price target of $12. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0. The higher price target estimate is at $12 while the lower price estimates are fixed at $12.

    Many Analysts from different Brokerage Firms have commented on the company rating and price targets.Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) rose by 8.38% in the past week and 10.45% for the past 4 weeks. For the past week, the counter has outperformed the S&P 500 by 9.74% and the outperformance increases to 13.26% for the past 4 weeks.

    Northwest Biotherapeutics, Inc (NASDAQ:NWBO), A drop of 45,778 shares or 0.5% was seen in the short interest of Northwest Biotherapeutics, Inc.. Even as the interest dropped from 8,728,180 shares on December 15,2014 to 8,682,402 shares on December 31,2014, the days to cover came in at 21. The updated interest stood at 24.2% of the stocks floats. The counter has an average daily volume of 421,686 shares.

    Northwest Biotherapeutics, Inc (NASDAQ:NWBO) ended the trading day with a decline of 0.47% or 0.03 points. The intraday bulls never looked convincing as the stock moved only negligibly above the opening price but dropped well below it. The opening trade was registered at $6.36 and the price peaked for the day at $6.55. The level of $6.3 acted as a support and the last transaction was made at $6.31. Volume had zoomed to 720,960 shares. The previous closing price is entered as $6.34. The 52-week low of the share price is $3.79. The company has a market cap of $393 million.

    Sentiment: Strong Buy

  • Reply to

    closing in the red today is NOT good

    by cartilio9rubo Jan 20, 2015 4:19 PM
    patriot1045 patriot1045 Jan 20, 2015 8:14 PM Flag

    I saw that block trade and price jumped immediately!!

    Sentiment: Strong Buy

  • Sunday, January 18, 2015


    Northwest Biotherapeutics, Inc. (NWBO) BUY ~ 5 Day Price Target: $7.25 Issued 01/18/2015 By Sierra Equity Sunday, January 18, 2015

    Sentiment: Strong Buy

  • Stocks to Keep Your Eyes on -Northwest Biotherapeutics, (NWBO),PIRAEUS BANK (BPIRY),Danske Bank A/S (DNSKY),Medican Enterprises Inc(OTCMKTS:MDCN)

    Submitted By Editor PSE on January 17, 2015 - 02:53 PM

    Sentiment: Strong Buy

  • From Linda's SF presentation: Nobody in the research community yet knows entirely why are the non-responders… non-responders. A strong possibility is that these patients don’t have enough activated T-Cells in the first place for checkpoint inhibitor drugs to do any good. If you don’t have the immune system activated and mobilized, the off-switches are not mobilized, and there is nothing for a checkpoint inhibitor drug to do. Well what does our technology DCVax do? It activates and mobilizes T-Cells. And it does so in a very big way. And it does so in a non-toxic way, as we’ve already talked about. And not only does it do it in a big way and a non-toxic way, it does it in a broad spectrum way. Each of these other elements, these checkpoints, are all rifle shots; and if you’ve noticed the combination treatment regimens that have been tried so far are combinations of rifle shots with rifle shots. As far as we’re aware, nobody has yet combined a rifle shot with a broad spectrum treatment, which is what our DCVax is. So we see a great opportunity for mutual benefit to at least test the concept of whether DCVax can mobilize T-cells and turn some of those non-responders into responders. That would obviously be very valuable for Big Pharma.

    Sentiment: Strong Buy

  • patriot1045 patriot1045 Jan 14, 2015 6:40 AM Flag

    From Linda's speech in SF: Third activity area will be continuation of all of the preparation and program building and ramp up of our early commercialization, if you want to call it that, in other words, the early roll out of our product, and collection of payment for it, under the early access program approvals that we’ve gotten in Germany, and… hopefully, we’ll receive in the UK.

    We will pursue that special approval stage two, the actual decision under the EAMS program in the UK, the second and final stage of that process. We’ll do that this year. We will continue the negotiations, which have so far been ongoing for months with the health insurance funds in Germany for the pricing and the reimbursement of our product. We are not going to rush that process. That process can very often take a full year of negotiation, sometimes longer. We want to make sure we come out with good reimbursement levels, and we are working on that. We are encouraged so far.

    Sentiment: Strong Buy

  • Reply to

    UCLA feels FDA approval coming. Read :

    by stirfry123 Jan 9, 2015 10:22 PM
    patriot1045 patriot1045 Jan 10, 2015 7:38 AM Flag

    In reporting on our innovative technology and latest research endeavors, we share the stories of how we have profoundly improved the quality of life and, in many cases, saved the lives of our patients and their families. We use a 360-degree integrative and multidisciplinary team approach to patient care that translates into superior clinical outcomes.

    Ronald Reagan UCLA Medical Center consistently ranks number one on the West Coast and in the top five in the nation, according to U.S. News and World Report. The UCLA Department of Neurosurgery also ranks year after year in the top 10 in the world according to U.S. News and World Report. Our high annual rankings are the result of our patients’ successes combined with our innovation to translate science and technology into medical breakthroughs at the bedside.

    Sentiment: Strong Buy

  • Reply to

    UCLA feels FDA approval coming. Read :

    by stirfry123 Jan 9, 2015 10:22 PM
    patriot1045 patriot1045 Jan 10, 2015 7:36 AM Flag

    The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of patients with brain tumors living longer than patients treated at any other hospital. Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in Phase III clinical trials in 46 centers throughout America. It is on the road to FDA approval as well as clinical trials throughout Europe. Using this vaccine, we are harnessing the patient’s immune system, genetics, pathology, brain mapping and a wide database of bioinformatics to optimize outcomes.

    Sentiment: Strong Buy

  • Reply to

    not if but when fda approves l...

    by sprokerrocker Jan 10, 2015 7:17 AM
    patriot1045 patriot1045 Jan 10, 2015 7:33 AM Flag

    If you are talking DCVax-L, then we could open at $20, $50 or $100+ depending upon what the market places valuation for brain cancer. NWBO also has Germany and UK so the valuation could be much higher as they would include major markets outside of the US. Direct could be massive if the data continues to mature and patients in the Phase I had failed all other treatment options and were going into palliative care with only months to live. Allan Butler, Direct patient with Stage IV pancreatic cancer is still living and back to work 24 months and counting since diagnosed. Just my 2 cents

    Sentiment: Strong Buy

  • patriot1045 patriot1045 Jan 5, 2015 2:03 PM Flag

    Yes they are listing as one of the presenting companies, does not tell you what date and time

    Sentiment: Strong Buy

  • Buying picking up like yesterday

    Sentiment: Strong Buy

  • Health-care sector taking a broad beating as pricing fears grow

    MARKETWATCH 2:39 PM ET 12/23/2014

    JNJ 104.1217 -2.6183 (-2.45%)
    MRK 57.14up -1.82 (-3.09%)
    GILD 89.169 -3.731 (-4.02%)
    ESRX 85.79down +3.455 (+4.2%)
    ABBV 64.4582up -2.5118 (-3.75%)
    QUOTES AS OF 03:13:20 PM ET 12/23/2014

    The health-care sector was taking a broad beating in afternoon trade Tuesday, as concerns over drug pricing grew. The SPDR Health Care Select Sector ETF (XLV) , or "XLV," was down 2.3%. Among the XLV's most heavily-weighted members, the shares of Johnson & Johnson(JNJ) dropped 2.5%, of Pfizer (PFE) fell 2.4% and of Merck & Co.'s(MRK) slid 2.9% . Those stocks were also the worst three performers within the Dow Jones Industrial Average on Tuesday. Gilead Sciences'(GILD) stock (GILD) shed 3.3%. , after the largest prescription-management company in the U.S., Express Scripts(ESRX) , dropped in favor a lower-priced drug from AbbVie(ABBV) . J.P. Morgan analyst Cory Kasimov said he had become increasingly concerned about the sustainability of branded drug pricing in the U.S. market, and Gilead's news "reinforce those fears above and beyond pricing pressures specifically related to [Gilead]." AbbVie's(ABBV) stock fell 3.8% while Express Scripts'(ESRX) shares rose 3.8%.

    Sentiment: Strong Buy

  • Reply to

    NWBO Volume and PPS Going Up Into Today's Close...

    by acec-stl Dec 19, 2014 3:27 PM
    patriot1045 patriot1045 Dec 19, 2014 4:01 PM Flag

    Nice 124,750 buy at close at $5.74!

    Sentiment: Strong Buy

  • Nice move up and some nice accumulation in last hour of trading today!

    Sentiment: Strong Buy

  • patriot1045 patriot1045 Dec 12, 2014 6:02 AM Flag

    Truly amazing considering how lethal Stage IV Lung cancer can be! The woman who could barely breathe due to size of tumor is now swimming, other non injected tumors are shrinking (systemic effect) and no side effects other than temperature. Got to love DCVax with no synthetic antigens using more potent dendritic cells via a blood draw to attack cancer cells is brilliant and it is working!!!!!

    Sentiment: Strong Buy

  • BETHESDA, Md. , Dec. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics(NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that NW Bio's CEO, Linda Powers, recapped the substantial progress made by the Company during 2014 in a presentation at Oppenheimer's 25th Annual Healthcare Conference in New York City.

    The presentation included updates about the DCVax-Direct Phase I trial, including emerging observations about the clinical results, two new case studies (in lung cancer and another type of sarcoma), and plans for the upcoming Phase II trials. The presentation also included brief updates about the expanding DCVax-L Phase III trial for GBM brain cancer, the early approval programs for DCVax-L in Germany and the UK, and the reimbursement negotiations process in Germany.

    Sentiment: Strong Buy

  • patriot1045 patriot1045 Dec 5, 2014 7:22 AM Flag

    I agree with you as pretty large ramp up in production for US, Germany and UK. This stock is still flying under the radar and went some of these catalyst's start to hit for HE, PIM Step 2 in UK, DCVax-L in Q1 2015 for possible halt for efficacy at 2nd interim. These regulatory agencies just do not move so quickly without extensive due diligence and review. I like my long term investment here especially after recent investment of $25M US by Woodford!

    Sentiment: Strong Buy

NWBO
7.37-0.09(-1.21%)Feb 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.